ArticleJournal for immunotherapy of cancer2023
Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG.
Erratum issuedOpen access · goldAbstract readMulticenter Study
In one paragraph
Article in Journal for immunotherapy of cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- Melanoma Brain Metastasis, Prognostic Factors, and Survival Outcomes After First Metastatic Line Therapy: A Monocentric Retrospective Study.Cancer medicine · 2026Observational
- Clinical, Dermatoscopic, Histological and Molecular Prognostic and Predictive Factors of Metastatic Melanoma Response to Immunotherapy: A Systematic Review and Drug Class Meta-Analysis.Journal of clinical medicine · 2026Review
- The safety and efficacy of encorafenib plus binimetinib for brain metastases: a systematic review and meta-analysis.Discover oncology · 2025Review
- HMGB3 promotes brain metastasis of lung adenocarcinoma by recruiting SSBP1 for nuclear translocation to remodel mitochondrial metabolism.Cancer communications (London, England) · 2025Article
- Improved Survival and Prognostication in Melanoma Patients With Brain Metastases: An Update of the Melanoma Graded Prognostic Assessment.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Article
- Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice.Journal of neuro-oncology · 2025Article
- Immune checkpoint inhibitor therapy is associated with a decreased risk of developing melanoma brain metastases.BJC reports · 2025Article
- Survival expectations in melanoma patients: a molecular prognostic model associated with aging.Discover oncology · 2025Article
- Predictive Impact of Tumor Mutational Burden on Real-World Outcomes of First-Line Immune Checkpoint Inhibition in Metastatic Melanoma.JCO precision oncology · 2024Article
- Immunotherapy Combined with Radiation in Malignant Melanoma without BRAF Mutations Brain Metastases-Favorable Response after Immunotherapy Continued beyond Progression.Journal of personalized medicine · 2024Article
Corrections and comments
- Erratum issued
Authors and funding
47 authors at 20 institutions in 1 country.
Cindy FranklinDepartment of Dermatology and Venereology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany cindy.franklin@uk-koeln.de.ORCID 0000-0001-9142-5423
Peter MohrDepartment of Dermatology, Elbe-Kliniken Buxtehude, Buxtehude, Germany.
Leonie BluhmDepartment of Dermatology, Elbe-Kliniken Buxtehude, Buxtehude, Germany.
Friedegund MeierDepartment of Dermatology, University Hospital Carl Gustav Carus, TU Dresden and, Skin Cancer Center at the University Cancer Center Dresden and National Center for Tumor Diseases (NCT), Dresden, Germany.ORCID 0000-0003-4340-9706
Marlene GarzarolliDepartment of Dermatology, University Hospital Carl Gustav Carus, TU Dresden and, Skin Cancer Center at the University Cancer Center Dresden and National Center for Tumor Diseases (NCT), Dresden, Germany.
Michael WeichenthalDepartment of Dermatology, Skin Cancer Center, Schleswig-Holstein University Hospital, Campus Kiel, Kiel, Germany.ORCID 0000-0002-9060-4961
Katharina KählerDepartment of Dermatology, Skin Cancer Center, Schleswig-Holstein University Hospital, Campus Kiel, Kiel, Germany.
Imke GrimmelmannSkin Cancer Center Hannover, Department of Dermatology, Hannover Medical School, Hanover, Germany.
Ralf GutzmerDepartment of Dermatology, Muehlenkreiskliniken Minden and Ruhr University Bochum, Minden, Germany.
Jochen UtikalSkin Cancer Unit, German Cancer Research Center (DKFZ) and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, Mannheim, Germany.
Patrick TerheydenDepartment of Dermatology, University of Lübeck and Schleswig-Holstein University Hospital, Campus Lübeck, Lübeck, Germany.ORCID 0000-0002-5894-1677
Rudolf HerbstDepartment of Dermatology, HELIOS Klinikum Erfurt, Erfurt, Germany.ORCID 0000-0002-4238-9486
Sebastian HaferkampDepartment of Dermatology, University Hospital Regensburg, Regensburg, Germany.
Claudia PfoehlerDepartment of Dermatology, Saarland University Medical School, Homburg, Homburg/Saar, Germany.
Andrea ForschnerDepartment of Dermatology, University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-6185-4945
Ulrike LeiterDepartment of Dermatology, University Hospital Tübingen, Tübingen, Germany.
Fabian ZillerDepartment of Dermatology, DRK Hospital Chemnitz-Rabenstein, Chemnitz, Germany.
Frank MeissDepartment of Dermatology and Venereology, Medical Center, University of Freiburg, Freiburg im Breisgau, Germany.
Jens UlrichDepartment of Dermatology and Skin Cancer Center, Harzklinikum Dorothea Christiane Erxleben, Quedlinburg, Germany.
Alexander KreuterDepartment of Dermatology, Venereology and Allergology, Helios St. Elisabeth Klinik Oberhausen, University Witten-Herdecke, Oberhausen, Germany.ORCID 0000-0003-2275-499X
Christoffer GebhardtDepartment of Dermatology and Venereology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0001-7090-9584
Julia WelzelDepartment of Dermatology and Allergology, University Hospital Augsburg, Augsburg, Germany.
Bastian SchillingDepartment of Dermatology and Venereology, University Hospital Würzburg, Würzburg, Germany.ORCID 0000-0001-8859-4103
Martin KaatzDepartment of Dermatology, SRH Wald-Klinikum Gera, Gera, Germany.
Karin Scharfetter-KochanekDepartment of Dermatology and Venereology, University Hospital Ulm, Ulm, Germany.
Edgar DippelDepartment of Dermatology, Ludwigshafen Medical Center, Ludwigshafen, Germany.
Dorothee NashanDepartment of Dermatology, Hospital of Dortmund, Dortmund, Germany.
Michael SachseSkin Cancer Center, Department of Dermatology, Klinikum Bremerhaven Reinkenheide, Bremerhaven, Germany.
Carsten WeishauptDepartment of Dermatology, University Hospital of Muenster, Muenster, Germany.
Harald LöfflerDepartment of Dermatology, SLK-Kliniken Heilbronn, Heilbronn, Germany.
Thilo GambichlerDepartment of Dermatology, Ruhr-University Bochum, Bochum, Germany.ORCID 0000-0001-7862-3695
Carmen LoquaiDepartment of Dermatology, Klinikum Bremen-Ost, Gesundheit Nord gGmbH, Bremen, Germany.
Lucie HeinzerlingDepartment of Dermatology and Allergology, Ludwig-Maximilian University, Munich, Germany.ORCID 0000-0002-9074-8017
Stephan GrabbeDepartment of Dermatology, University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.
Dirk DebusDepartment of Dermatology, Nuremberg General Hospital, Paracelsus Medical University, Nuremberg, Germany.
Gaston SchleyDepartment of Dermatology and Venereology, Helios Klinikum Schwerin, Schwerin, Germany.
Jessica C HasselNational Center for Tumor Diseases (NCT), Department of Dermatology, University Hospital Heidelberg, Heidelberg, Germany.ORCID 0000-0001-7575-6230
Gerhard WeyandtDepartment of Dermatology and Allergology, Hospital Bayreuth, Bayreuth, Germany.
Maike TrommerDepartment of Radiation Oncology and Cyberknife Center, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.ORCID 0000-0003-2864-4273
Georg LoddeDepartment of Dermatology, Venereology and Allergology, University Hospital Essen and German Cancer Consortium (DKTK) Partner Site Essen, Essen, Germany.
Jan-Malte PlackeDepartment of Dermatology, Venereology and Allergology, University Hospital Essen and German Cancer Consortium (DKTK) Partner Site Essen, Essen, Germany.ORCID 0000-0002-7842-4669
Lisa ZimmerDepartment of Dermatology, Venereology and Allergology, University Hospital Essen and German Cancer Consortium (DKTK) Partner Site Essen, Essen, Germany.
Elisabeth LivingstoneDepartment of Dermatology, Venereology and Allergology, University Hospital Essen and German Cancer Consortium (DKTK) Partner Site Essen, Essen, Germany.
Jürgen Christian BeckerDepartment of Dermatology, Venereology and Allergology, University Hospital Essen and German Cancer Consortium (DKTK) Partner Site Essen, Essen, Germany.ORCID 0000-0001-9183-653X
Susanne HornDepartment of Dermatology, Venereology and Allergology, University Hospital Essen and German Cancer Consortium (DKTK) Partner Site Essen, Essen, Germany.
Dirk SchadendorfDepartment of Dermatology, Venereology and Allergology, University Hospital Essen and German Cancer Consortium (DKTK) Partner Site Essen, Essen, Germany.
Selma UgurelDepartment of Dermatology, Venereology and Allergology, University Hospital Essen and German Cancer Consortium (DKTK) Partner Site Essen, Essen, Germany.ORCID 0000-0002-9384-6704
Essen University Hospital · DEElbe Kliniken Stade-Buxtehude · DEGerman Cancer Research Center · DEJohannes Gutenberg University Mainz · DENational Center for Tumor Diseases · DEUniversity Children's Hospital Tübingen · DEUniversity Hospital Schleswig-Holstein · DEUniversity of Cologne · DEBayreuth Medical Center · DEHeidelberg University · DEHelios Hospital Schwerin · DEHelios Klinikum Erfurt · DEHELIOS St. Elisabeth Klinik Oberhausen · DEJohannes Wesling Klinikum Minden · DEKlinikum Bremerhaven-Reinkenheide · DEKlinikum Chemnitz · DEKlinikum Dortmund · DEKlinikum Ludwigshafen · DELudwig-Maximilians-Universität München · DEMedizinische Hochschule Hannover · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite the availability of effective systemic therapies, a significant number of advanced melanoma patients develops brain metastases. This study investigated differences in incidence and time to diagnosis of brain metastasis and survival outcomes dependent on the type of first-line therapy.
methodsPatients with metastatic, non-resectable melanoma (AJCCv8 stage IIIC-V) without brain metastasis at start of first-line therapy (1L-therapy) were identified from the prospective multicenter real-world skin cancer registry ADOREG. Study endpoints were incidence of brain metastasis, brain metastasis-free survival (BMFS), progression-free survival (PFS), and overall survival (OS).
resultsOf 1704 patients, 916 were BRAF wild-type (BRAF
conclusionsIn BRAF
Indexed as
Brain NeoplasmsMelanomaSkin NeoplasmsBrainCTLA-4 AntigenHumansMitogen-Activated Protein Kinase KinasesProgrammed Cell Death 1 ReceptorProspective StudiesProto-Oncogene Proteins B-rafRegistriesCTLA-4 AntigenMitogen-Activated Protein Kinase KinasesProgrammed Cell Death 1 ReceptorProto-Oncogene Proteins B-rafmelanoma
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.